A Study of HS-20106 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

NCT06594965 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

176

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndromes
Anemia
MDS
Bone Marrow Disease

Interventions

DRUG: HS-20106

Sponsor

Hansoh BioMedical R&D Company